Leif P. Bergsagel

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Shaji Kumar, Suzanne R. Hayman, Francis K. Buadi et al. · Blood · 2012 · 124 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +9

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB

Yulia N. Demchenko, Leslie A. Brents, Zhihong Li et al. · Oncotarget · 2014 · 66 citations · Full text

Medicine, Cancer Biology, Oncology +12

Targeting vasculogenesis to prevent progression in multiple myeloma

Michele Moschetta, Yuji Mishima, Yawara Kawano et al. · Leukemia · 2016 · 49 citations

Medicine, Hematology, Oncology +12

Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy

Shaji Kumar, J. Mikhael, Betsy LaPlant et al. · Bone Marrow Transplantation · 2013 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +17